Novo-Nordisk A/SNVO
Closing prices as of Sep 15, 2026Updated once daily after the US close — not a live quote.

$42.63

-5.81% past month

Notable price movement

  • Sep 15, 2026

    $42.53-2.12%

    Novo Nordisk shares fell 2.12% on the day, a move not shared by the broad market, which slipped only 0.46% on the S&P 500 ETF (SPY) .

  • Sep 14, 2026

    $43.45+0.88%

    Novo Nordisk shares rose 0.88% on the day it was reported that the company had rebranded itself as ‘Novo’ in a push to win back the obesity market .

  • Sep 11, 2026

    $43.07-2.14%

    Novo Nordisk shares fell 2.14% on the day even as the broad market moved higher, with the S&P 500 ETF (SPY) up 0.85% in the same session . The decline was not shared by the broader market .

  • Sep 10, 2026

    $44.01-1.23%

  • Sep 9, 2026

    $44.56-1.33%

  • Sep 8, 2026

    $45.16-3.09%

    Novo Nordisk shares fell after the company halted two heart drug trials , even as it separately reported positive semaglutide trial results in young children . The decline was far larger than the broad market's move, with the S&P 500 ETF (SPY) down only 0.55% the same session .

  • Sep 4, 2026

    $46.60-1.92%

Closing prices for NVO. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Recent news

Seeking Alpha1 day agoNovo CEO seeks a more consumer-centric culture from employeesThe Motley Fool1 day agoEli Lilly's Momentum Looks Unstoppable -- but 1 Factor Could Change EverythingGlobenewswireAug 24, 2026Novo Resources Releases Updated Corporate PresentationSeeking Alpha1 day agoEli Lilly has more than 30% of new patients on oral weight-loss meds: execThe Motley Fool1 day ago3 Absurdly Cheap Growth Stocks to Buy Before the End of 2026Seeking Alpha2 days agoWall Street Breakfast Podcast: Oil's New Chokepoint

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.

Prices and financial data are historical and provided for research only. Not investment advice.